Graph Therapeutics Raises $5M for Immune Therapy Development

Vienna-based Graph Therapeutics has successfully closed a $5 million funding round, signaling a significant step forward in its mission to develop novel immunotherapies. The investment, led by Paris-based venture capital firm Daphni, will fuel the company's transition from platform development to the clinical advancement of its therapeutic programs targeting inflammatory and immune-mediated diseases.

This latest capital infusion brings Graph Therapeutics' total funding to over $10 million, including non-dilutive grants. The round saw participation from existing investors, including SquareOne Venture Capital, Merantix Capital, and NAVEC Investment Management. The continued support from these key backers underscores confidence in the company's innovative approach and its potential to address unmet medical needs in immunology.

The strategic reallocation of resources will prioritize Graph Therapeutics' internal drug discovery initiatives. The company aims to leverage its proprietary 'Lab-in-the-loop' technology, which synergizes live patient cell models with machine learning algorithms. This sophisticated platform allows for the deep analysis of complex immune functions, enabling the identification of disease mechanisms, drug targets, and predictive biomarkers from multi-omics data and primary patient cells.

This funding round is particularly noteworthy given the challenging biotech funding environment. The global biotechnology sector, while experiencing robust long-term growth driven by advancements in genomics and personalized medicine, often faces funding volatility. Graph Therapeutics' success highlights the appeal of deep-tech ventures with strong scientific foundations and clear therapeutic potential. The company's focus on leveraging AI for drug discovery aligns with a broader industry trend where computational approaches are accelerating R&D timelines and improving success rates.

Further bolstering Graph Therapeutics' financial foundation are significant non-dilutive grants from Austrian public funding bodies. The Forschungsförderungsgesellschaft (FFG) and the Austria Wirtschaftsservice (aws) have provided crucial support through programs like 'Austrian Life Sciences' and 'Deep Tech Life Sciences Seed Financing'. This blend of private and public funding is a testament to Austria's commitment to fostering innovation in the life sciences sector and provides a stable base for the company's ambitious research and development pipeline.

The leadership team at Graph Therapeutics brings a wealth of experience, particularly in AI-driven precision oncology, having previously been involved with Allcyte, a company that was acquired by Exscientia. This background provides a strong foundation for navigating the complexities of drug development and commercialization. The company also plans to expand its platform capabilities and establish strategic partnerships, potentially opening avenues for out-licensing opportunities and further validating its technology.